US 12325854
Crispr-CPF1-related methods, compositions and components for cancer immunotherapy
granted A61KA61K35/17A61P
Quick answer
US patent 12325854 (Crispr-CPF1-related methods, compositions and components for cancer immunotherapy) held by Editas Medicine, Inc. expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Editas Medicine, Inc.
- Grant date
- Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K35/17, A61P, A61P35/00, A61P35/02